Skip to content
Search

Latest Stories

SS Rajamouli’s RRR gets postponed to 2021

After the Baahubali franchise, director SS Rajamouli is working on a film titled RRR. The movie is said to be based in the pre-independence era and stars N. T. Rama Rao Jr., Ram Charan, Alia Bhatt, and Ajay Devgn.

The movie was supposed to hit the screens in July this year, but it has been postponed to January 2021. On the official Instagram account of the film, the makers posted, “Your love and support have made all our hard work and hectic schedules worthwhile! We are working round the clock to give you a cinematic experience like never before. And with a huge worldwide release planned, we have had to postpone the date of release. We understand this is a disappointment, but there's going to be a lot to look forward to because this only gives us more time to bring the best to you. #RRR will hit the screens on January 8th, 2021! We know the wait is long but we promise to keep giving you updates in the meanwhile. #RRROnJan8th #RRR.”


The shooting of the film started in November 2018. A few days ago, Ajay Devgn joined the team to shoot for his extended cameo in the movie. The makers had posted about it on Instagram, “All of us are super charged and ecstatic to kickstart our schedule with @ajaydevgn ji today... Welcome Sir! #AjayDevgn #RRRMovie #RRR.”

Well, reportedly, even Alia Bhatt has a small role to play in the film. But the actress is super excited to team up with the director SS Rajamouli. While RRR is being made in Telugu, it will get a huge release in Hindi as well just like the Baahubali franchise.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less